Japan Lifeline Co., Ltd.
7575・Prime Market・Wholesale Trade
Japan Lifeline Co., Ltd. (Single Segment)
Manufacturer and distributor of medical devices centered on the cardiovascular field
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (full year, financial results actual) | ¥59,187 million | ¥56,610 million | ↑ |
| Operating profit (full year, financial results actual) | ¥12,606 million | ¥12,326 million | ↑ |
| Operating margin (full year, financial results actual) | 21.3% | 21.8% | ↓ |
| Ordinary profit (full year, financial results actual) | ¥12,588 million | ¥12,335 million | ↑ |
| Profit attributable to owners of parent (full year, financial results actual) | ¥9,350 million | ¥9,317 million | ↑ |
| Gross margin (full year, financial results actual) | 59.4% | 60.4% | ↓ |
| Equity ratio (period-end, financial results actual) | 82.1% | 79.8% | ↑ |
| Earnings per share (full year, financial results actual) | ¥133.30 | ¥131.43 | ↑ |
| Net assets per share (period-end, financial results actual) | ¥938.65 | ¥854.74 | ↑ |
| Annual dividend (actual) | ¥54.00 | ¥53.00 | ↑ |
| Payout ratio (full year, financial results actual) | 40.5% | 40.3% | ↑ |
| Operating cash flow (full year, financial results actual) | ¥8,172 million | ¥9,113 million | ↓ |
| Cash and cash equivalents at period-end (financial results actual) | ¥12,494 million | ¥11,014 million | ↑ |
| Net sales (FY2027 (ending March 2027) full-year forecast) | ¥63,200 million | ¥59,187 million | ↑ |
| Operating profit (FY2027 (ending March 2027) full-year forecast) | ¥10,700 million | ¥12,606 million | ↓ |
Business Details
The company manufactures, imports, and sells medical devices primarily for the cardiovascular field, with general hospitals in Japan as its main customers. Its distinguishing feature is a hybrid business model combining manufacturer functions (proprietary products) with trading company functions (importing superior overseas products). Its product lineup is organized into five categories: Rhythm Device, EP/Ablation, Cardiovascular, Cerebrovascular, and Gastroenterology. The company has established a unique position within the industry through its own nationwide sales network. Approximately 70% of merchandise purchases are yen-denominated transactions, limiting the short-term impact of exchange rate fluctuations.
Recent Overview
FY2026 (ending March 2026) set record highs across all metrics, but a significant profit decline is forecast for the following year due to increased strategic investment
In FY2026 (ending March 2026), net sales reached ¥59,187 million (up 4.6% year on year) and operating profit reached ¥12,606 million (up 2.3% year on year), setting record highs across all metrics. Strong growth in Cerebrovascular (+44.5%) and Gastroenterology (+17.4%) drove the results. On the other hand, the proprietary product ratio declined (56.0%, down 1.4pt year on year) due to the spread of PFA, and SG&A expenses increased (+¥703 million), causing the operating margin to fall to 21.3% (down 0.5pt year on year). For FY2027 (ending March 2027), net sales are forecast to increase 6.8%, while SG&A expenses are expected to rise 14.3% year on year due to accelerated R&D spending for PFA and overseas expansion, wage increases, and head office relocation costs, among other factors, resulting in a forecast operating profit of ¥10,700 million (down 15.1% year on year), a substantial decline. The annual dividend is planned to increase to ¥56 (payout ratio of 49.1%).
Key Products
Growth Drivers
- Expanding demand for EP/Ablation products (forecast +9.5% revenue growth) driven by the continued increase in atrial fibrillation ablation case volumes (FY2027 (ending March 2027) expected to increase approximately 9% year on year)
- Establishment of a new growth driver through the full release in March 2026 of the proprietary high-frequency wire for atrial septal puncture, 'XEROstar'
- Expanded case coverage through an increase in the number of facilities newly adopting femoral vein hemostasis devices and the introduction of new sizes
- Continued double-digit growth in the new fields of Cerebrovascular and Gastroenterology (double-digit growth also expected in FY2027 (ending March 2027) due to expanding share of mainstay products)
- Expansion of market share in Frozen Elephant Trunk and artificial blood vessels (artificial blood vessel share expansion benefiting from competitors' reduced product lineups)
- Creation of medium- to long-term growth opportunities through advancement of R&D for Pulse Field Ablation (PFA) systems and expansion into overseas markets
- Diversification of domestic risk and establishment of new revenue sources through the medium-term management plan's key initiatives of 'expanding global sales' and 'promoting OEM manufacturing'
Risks
- Decline in average selling prices due to continued reductions in insurance reimbursement prices (the FY2027 (ending March 2027) forecast also incorporates price declines from official price revisions)
- Decline in demand for existing EP catheter products such as esophageal temperature monitoring catheters, and a decline in the proprietary product ratio, due to the rapid adoption of PFA (Pulse Field Ablation)
- Risk of a substantial decline in operating profit for FY2027 (ending March 2027) (down 15.1% year on year) due to increased strategic expenses related to PFA, overseas expansion, wage increases, and head office relocation
- Rising manufacturing costs due to increased raw material and labor costs, coupled with difficulty passing on price increases under the official pricing system (gross margin for FY2027 (ending March 2027) forecast at 57.9%, down 1.5pt year on year)
- Expanding market share of competitors' leadless pacemakers in the pacemaker market, and entry of competitors' new products into the S-ICD market
- Risk of intensified competition and loss of market share due to new entrants from competitors in intracardiac defibrillation catheters and FET
- Foreign exchange risk from the approximately 30% of merchandise purchases denominated in foreign currency (although the impact is smoothed through application of the moving average method, excessive yen depreciation would have a negative long-term impact on performance)
- Structural increase in SG&A expenses due to price increases for IT systems and various services under an inflationary environment, along with rising personnel costs
Last updated: June 19, 2026